Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.48 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16997481 | 0.86 | HPGD (0.52) | PTGDR2DGAT1KDM4ELMNAHTT | |
| SCHEMBL989347 | 0.84 | PTGDR2 (0.68) | PTGDR2KDM4ELMNAHTTMEN1 | |
| SCHEMBL27685280 | 0.82 | PTGDR2 (0.49) | PTGDR2DGAT1KDM4EPARP1PARP15 | |
| SCHEMBL3364550 | 0.82 | PTGDR2 (0.53) | PTGDR2DGAT1LMNAMAPTKMT2A | |
| SCHEMBL27684806 | 0.82 | PTGDR2 (0.50) | PTGDR2DGAT1KDM4ELMNAHTT | |
| SCHEMBL8336977 | 0.82 | HTT (0.65) | PTGDR2DGAT1KDM4ELMNAHTT | |
| SCHEMBL8334827 | 0.81 | PTGDR2 (0.46) | PTGDR2KDM4ELMNAHTTMEN1 | |
| SCHEMBL8334713 | 0.81 | PTGDR2 (0.46) | PTGDR2KDM4ELMNAHTTMEN1 | |
| SCHEMBL17018092 | 0.80 | PTGDR2 (0.48) | PTGDR2KDM4EHTTCYP3A4MAPT | |
| SCHEMBL8337397 | 0.79 | PDE4A (0.54) | PTGDR2KDM4ELMNAMEN1NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180064726-A1 | Deuterium-Substituted Oxazepin Compounds | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2018-03-08 | — | — | US | disclosed |
| US-20160332977-A1 | PROCESSES FOR PREPARING FUSED HETEROCYCLIC ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2016-11-17 | — | — | US | disclosed |
| US-20160332976-A1 | PROCESSES FOR PREPARING FUSED HETEROCYCLIC ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2016-11-17 | — | — | US | disclosed |
| US-20160332977-A1 | PROCESSES FOR PREPARING FUSED HETEROCYCLIC ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2016-11-17 | — | — | US | disclosed |
| US-20160332976-A1 | PROCESSES FOR PREPARING FUSED HETEROCYCLIC ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2016-11-17 | — | — | US | disclosed |
| WO-2015123519-A2 | PROCESSES FOR PREPARING FUSED HETEROCYCLIC ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2015-08-20 | — | — | WO | disclosed |
| US-20150225384-A1 | PROCESSES FOR PREPARING FUSED HETEROCYCLIC ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2015-08-13 | — | — | US | disclosed |
| US-20150225384-A1 | PROCESSES FOR PREPARING FUSED HETEROCYCLIC ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332976-A1 | PROCESSES FOR PREPARING FUSED HETEROCYCLIC ION CHANNEL MODULATORS | KCNN2, KCNJ2, KCNN1 | PTGDR2 1450/4885DGAT1 2573/4885KDM4E 1924/4885 |
| US-20180064726-A1 | Deuterium-Substituted Oxazepin Compounds | HCN1, KCNN1, CACNA1I | PTGDR2 155/4885DGAT1 1156/4885KDM4E 2863/4885 |
| US-20160332977-A1 | PROCESSES FOR PREPARING FUSED HETEROCYCLIC ION CHANNEL MODULATORS | KCNN2, KCNJ2, KCNN1 | PTGDR2 1450/4885DGAT1 2573/4885KDM4E 1924/4885 |
| US-20150225384-A1 | PROCESSES FOR PREPARING FUSED HETEROCYCLIC ION CHANNEL MODULATORS | KCNN2, KCNJ2, KCNN1 | PTGDR2 1450/4885DGAT1 2573/4885KDM4E 1924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.